Her2 gene polymorphisms are likely associated with cardiotoxicity from anti-HER2 therapies in breast cancer, but evidence is inconclusive for clinical testing.
Do HER2 gene polymorphisms predict cardiotoxicity in adult patients with HER2-positive breast cancer treated with anti-HER2 targeted therapy?
Current evidence regarding the association between HER2 genetic polymorphisms and anti-HER2 induced cardiotoxicity is inconclusive and does not yet justify routine clinical implementation of genetic testing.
Absolute Event Rate: 0% vs 0%
Abstract Background Breast cancer is the leading cause of cancer death in women in Morocco and worldwide. The development of anti-HER2 therapies has improved the management of HER2-positive breast cancers. However, cardiotoxicity remains the major complication observed in patients undergoing this treatment and genetic factors appear to be involved in the predisposition to these cardiovascular toxicities. The present systematic review aims to further elucidate the relationship between some genetic polymorphisms and cardiotoxicity in HER2-positive breast cancers. Methods All relevant studies, that investigated the association between genetic variants and cardiotoxicity in adult patients with HER2-positive breast cancer treated with anti-HER2 targeted therapy, have been extracted from PubMed, Scopus, and Google Scholar databases up to February 2025. Results 15 studies were enrolled after strict literature screening. Most of them have analyzed HER2 gene polymorphisms, which are most likely associated with cardiotoxicity induced by anti-HER2 treatments; nevertheless, some findings are still inconclusive. Conclusion The current evidence does not yet justify clinical implementation of HER2 polymorphism testing. Larger studies such as multi-center cohorts including biomarkers and pharmacokinetic data are needed to confirm the effects of these genetic variants in predicting cardiotoxicity in patients with HER2-positive breast cancer.
Habbal et al. (Wed,) reported a other. Her2 gene polymorphisms are likely associated with cardiotoxicity from anti-HER2 therapies in breast cancer, but evidence is inconclusive for clinical testing.